Ventyx Biosciences (VTYX) Outlook Strengthened by Cost Optimization and Positive Clinical Data
Ventyx Biosciences Inc. (NASDAQ:VTYX) is among the hottest SMID-cap stocks so far in 2025.
Ventyx Biosciences Inc. (VTYX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 3,209,645 | $9,981,996 | -46% | 0.02% |
| 2. | Tang Capital Management Kevin C. Tang | 3,100,000 | $9,641,000 | 0.37% | |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,316,275 | $7,203,615 | -4% | 0.01% |
| 4. | Vestal Point Capital Ryan Wilder | 2,050,000 | $6,375,500 | +3% | 0.29% |
| 5. | Citadel Investment Group Ken Griffin | 1,879,989 | $5,846,766 | +7% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.31 | 130,000 | $300,573.00 | 130,000 | 2024-12-23 | Filing | |
| $2.01 | 261,752 | $524,943.64 | 2,175,028 | 2024-11-25 | Filing | |
| $1.83 | 238,248 | $434,945.55 | 1,913,276 | 2024-11-22 | Filing | |
| $16.00 | 625,000 | $10,000,000.00 | 1,410,303 | 2021-10-25 | Filing | |
| $16.00 | 312,500 | $5,000,000.00 | 3,997,269 | 2021-10-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.07 | 1,887 | $2,019.09 | 467,226 | 2025-04-02 | Filing | |
| $2.36 | 21,119 | $49,840.84 | 464,582 | 2024-12-27 | Filing | |
| $2.26 | 13,161 | $29,682.00 | 485,701 | 2024-12-19 | Filing | |
| $5.40 | 1,651 | $8,921.34 | 284,999 | 2024-04-02 | Filing | |
| $5.40 | 1,651 | $8,921.01 | 264,998 | 2024-04-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,924,415 | $12,204,931 | 1.06% | |
| 2. | 3,769,997 | $11,724,691 | 0% | |
| 3. | 1,183,240 | $3,679,877 | 0% | |
| 4. | 1,059,823 | $3,296,050 | 0.01% | |
| 5. | 748,088 | $2,326,554 | 0% |
News See All
10 Hottest SMID-Cap Stocks So Far In 2025
SMID-caps, or Small- and mid-cap stocks, are often overlooked segments of the market.
Ventyx Biosciences Reports Positive Phase 2 Data for Oral NLRP3 Inhibitor VTX3232 in Obesity and Cardiovascular Risk
Ventyx Biosciences Inc. (NASDAQ:VTYX) is one of the best NASDAQ stocks under $5 to buy now.
11 Best NASDAQ Stocks Under $5 to Buy Now
On October 9, Scott Ladner, Chief Investment Officer at Horizon Investments, appeared on CNBC to suggest that AI remains the key market driver along with tech.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen and welcome to the Ventyx Biosciences First Quarter 2024 Earnings Conference Call.
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
25 Biggest Stocks with Negative Beta
Stock markets were in see-saw mode before the Fed’s September decision on rate hikes.
Long-Term Returns of Dan Loeb's 5 Activist Targets
The investment came amid Loeb’s confidence about SentinelOne, Inc. (NYSE:S)’s growth potential and ability to disrupt the cyber security industry.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Second Quarter 2023 Earnings Conference Call.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences First Quarter 2023 Earnings Conference Call.
Hedge Fund Resource Center Billionaire Hedge Funds
